Investors are on the edge of their collective seats, hoping Cambrex
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Cambrex with analysts unanimously rating it hold. Analysts don't like Cambrex as much as competitor SeraCare Life overall. Three out of four analysts rate SeraCare Life a buy compared with zero of two for Cambrex. Analysts haven't adjusted their rating of Cambrex for the past three months.
- Revenue Forecasts: On average, analysts predict $54.9 million in revenue this quarter. That would represent a rise of 12.3% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.07 per share. Estimates range from $0.06 to $0.08.
What our community says:
CAPS All-Stars are solidly behind the stock with 83.3% awarding it an "outperform" rating. The community at large agrees with the All-Stars with 78.1% granting it a rating of "outperform." Fools are bullish on Cambrex, though the message boards have been quiet lately with only 21 posts in the past 30 days. Cambrex's bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Revenue has now gone up for three straight quarters. The company's gross margin shrank by 2.9 percentage points in the last quarter. Revenue rose 17.5% while cost of sales rose 22.4% to $49.3 million from a year earlier.
For all our Cambrex-specific analysis, including earnings and beyond, add Cambrex to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Stocks You Can Buy on Sale
Investors looking for cheap stocks to buy right now should consider General Electric, Kinder Morgan, and Cambrex Corporation.
Pharma Manufacturer Cambrex Corporation Rose as Much as 19.3% on Strong Earnings
The company announced an 8% rise in quarterly revenue and a 73% increase in cash compared to June, and raised its full-year 2016 guidance.
This Under-the-Radar Stock Powers the Pharma Industry -- and It Just Raised 2016 Guidance
Cambrex Corporation manufactures active pharmaceutical ingredients for dozens of therapeutics used everyday. You could say it’s having a pretty good run.